Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Gentile

Showing results (231-240 of 313) with videos related to

Pageof 32
Sort By:
European Journal of Haematology|March 11, 2015
Prospective validation of predictive value of abdominal computed tomography scan on time to first treatment in Rai 0 chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL studyMassimo Gentile, Giovanna Cutrona, Stefano Molica, et al.
Blood|September 29, 2011
Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairmentFortunato Morabito, Massimo Gentile, Carla Mazzone, et al.
Cancers|June 10, 2023
Antibody Response to the SARS-CoV-2 Vaccine and COVID-19 Vulnerability during the Omicron Pandemic in Patients with CLL: Two-Year Follow-Up of a Multicenter StudyFrancesca R Mauro, Diana Giannarelli, Clementina M Galluzzo, et al.
Pharmaceuticals (Basel, Switzerland)|April 26, 2025
Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID StudyNicola Sgherza, Olga Battisti, Paola Curci, et al.
Eclinicalmedicine|July 3, 2023
Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencingStefania Oliva, Elisa Genuardi, Laura Paris, et al.
Haematologica|October 5, 2019
Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trialSara Bringhen, Mattia D'Agostino, Laura Paris, et al.
Frontiers in Oncology|August 19, 2021
Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic LeukemiaFortunato Morabito, Giovanni Tripepi, Riccardo Moia, et al.
Cancers|June 24, 2022
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) CellsCaterina Riillo, Daniele Caracciolo, Katia Grillone, et al.
Frontiers in Oncology|December 8, 2022
Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus studyAndrea Visentin, Francesca Romana Mauro, Gioachino Catania, et al.
Leukemia & Lymphoma|July 7, 2020
Primary refractory multiple myeloma: a real-world experience with 85 casesArtur Jurczyszyn, Anna Waszczuk-Gajda, Jorge J Castillo, et al.
Pageof 32

Showing results (231-240 of 313) with videos related to

Sort By:
Pageof 32
European Journal of Haematology|March 11, 2015
Prospective validation of predictive value of abdominal computed tomography scan on time to first treatment in Rai 0 chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL studyMassimo Gentile, Giovanna Cutrona, Stefano Molica, et al.
Blood|September 29, 2011
Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairmentFortunato Morabito, Massimo Gentile, Carla Mazzone, et al.
Cancers|June 10, 2023
Antibody Response to the SARS-CoV-2 Vaccine and COVID-19 Vulnerability during the Omicron Pandemic in Patients with CLL: Two-Year Follow-Up of a Multicenter StudyFrancesca R Mauro, Diana Giannarelli, Clementina M Galluzzo, et al.
Pharmaceuticals (Basel, Switzerland)|April 26, 2025
Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID StudyNicola Sgherza, Olga Battisti, Paola Curci, et al.
Eclinicalmedicine|July 3, 2023
Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencingStefania Oliva, Elisa Genuardi, Laura Paris, et al.
Haematologica|October 5, 2019
Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trialSara Bringhen, Mattia D'Agostino, Laura Paris, et al.
Frontiers in Oncology|August 19, 2021
Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic LeukemiaFortunato Morabito, Giovanni Tripepi, Riccardo Moia, et al.
Cancers|June 24, 2022
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) CellsCaterina Riillo, Daniele Caracciolo, Katia Grillone, et al.
Frontiers in Oncology|December 8, 2022
Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus studyAndrea Visentin, Francesca Romana Mauro, Gioachino Catania, et al.
Leukemia & Lymphoma|July 7, 2020
Primary refractory multiple myeloma: a real-world experience with 85 casesArtur Jurczyszyn, Anna Waszczuk-Gajda, Jorge J Castillo, et al.
Pageof 32